The immunomodulatory activity of lenvatinib prompts the survival of patients with advanced hepatocellular carcinoma.

ABSTRACT:

Background

Lenvatinib is a novel multiple receptor tyrosine kinase inhibitor used for hepatocellular carcinoma (HCC) treatment. Although its main function is to suppress VEGFR and FGFR pathway, its immunomodulatory activity in HCC is not elucidated. Thus, this study aimed to investigate the immunomodulatory capability of lenvatinib in HCC.

Material and methods

Totally 47 patients with HCC were enrolled in this study, and the immune cells and serum cytokine profiles before initiation of treatment and after 1 and 3 months were measured. The immune checkpoint receptors on the immune cells were also evaluated. Kaplan-Meier survival estimate and log rank tests were used to assess the prognostic value.

Result

The frequency of T helper (Th) cells and T regulatory (Treg) cell

SUBMITTER: Zhu J 

PROVIDER: S-EPMC8607247 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature